GlassScriptPhysician profile
Sean W Maclean
NPI 1336584820
$2,919.10
in general payments reported to CMS, 2019-2025
27 companies · $53.35 in 2025
The $53.35 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,975 · 2020: $608 · 2021: $43.56 · 2022: $45.41 · 2023: $178 · 2024: $15.55 · 2025: $53.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $247.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $405.73 | 2019-2025 | Wegovy |
| Glaxosmithkline, LLC. | $317.66 | 2019-2020 | |
| Pfizer INC. | $267.44 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $259.53 | 2019-2020 | |
| Lilly USA, LLC | $208.62 | 2019-2023 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $190.83 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $173.74 | 2019-2020 | |
| Abbott Laboratories | $121.98 | 2019-2021 | |
| Amgen INC. | $117.54 | 2019-2025 | Otezla, Repatha |
| Silk Road Medical, INC. | $116.05 | 2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $91.89 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $87.46 | 2019-2020 | |
| Amarin Pharma, INC. | $86.90 | 2019-2020 | |
| Allergan, INC. | $84.49 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $83.66 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $69.68 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.91 | 2019 | |
| Merck Sharp & Dohme LLC | $37.76 | 2020 | |
| Lantheus Medical Imaging, INC. | $27.31 | 2019 | |
| Janssen Pharmaceuticals, INC | $25.36 | 2019 | |
| Genentech USA, INC. | $19.52 | 2020 | |
| Dexcom, INC. | $15.97 | 2023 | Dexcom G6 Transmitter |
| Seqirus USA INC | $15.55 | 2024 | Fluad, Flucelvax |
| Boston Scientific Corporation | $15.04 | 2025 | Watchman |
| Horizon Therapeutics Plc | $14.91 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.81 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Maclean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.